ARGEN-X
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
ARGEN-X
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2008-01-01
Address:
Rotterdam, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.argenx.com
Total Employee:
501+
Status:
Active
Contact:
+320477772944
Total Funding:
1.95 B USD
Technology used in webpage:
IPhone / Mobile Compatible SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET IIS Sectigo SSL Sectigo Domain SSL
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Immunovia
Immunovia is the center for translational cancer research in Lund, Sweden.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Employees Featured
Christophe Blanchetot Director Discovery @ arGEN-X
Director Discovery
2016-01-01
Keith Woods Chief Operating Officer @ arGEN-X
Chief Operating Officer
2018-01-01
Hans De Haard CSO @ arGEN-X
CSO
2008-01-01
Christophe Blanchetot Research Fellow @ arGEN-X
Research Fellow
2011-03-01
Eric Castaldi CFO @ arGEN-X
CFO
Founder
Stock Details
Investors List
Burrage Capital
Burrage Capital investment in Post-IPO Equity - arGEN-X
MPM Capital
MPM Capital investment in Post-IPO Equity - arGEN-X
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - arGEN-X
Aquila Capital
Aquila Capital investment in Post-IPO Equity - arGEN-X
Erasmus MC Biomedical Fund
Erasmus MC Biomedical Fund investment in Series B - arGEN-X
PMV
PMV investment in Series B - arGEN-X
Omnes Capital
Omnes Capital investment in Series B - arGEN-X
Seventure Partners
Seventure Partners investment in Series B - arGEN-X
OrbiMed
OrbiMed investment in Series B - arGEN-X
Forbion Capital Partners
Forbion Capital Partners investment in Series B - arGEN-X
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-02-06 | Halozyme Therapeutics | arGEN-X investment in Post-IPO Equity - Halozyme Therapeutics | 30 M USD |
Official Site Inspections
http://www.argenx.com Semrush global rank: 467.41 K Semrush visits lastest month: 110.13 K
- Host name: 151.101.3.10
- IP address: 151.101.3.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "arGEN-X"
About - One Team, One Culture, One Purpose - Argenx
Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership …See details»
Organization and Operations - argenx Annual Report 2023
Through argenx’s collaboration with Zai Lab, we have an interest in business operations in Greater China. Any unfavorable government policies on international trade, including tariffs, …See details»
argenx - Crunchbase Company Profile & Funding
Organization. argenx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. argenx is a global …See details»
argenx | Executive Management
Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership …See details»
Our Commitment to Patients - Argenx
Argenx is committed to improving the lives of people suffering from severe autoimmune diseases. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and hearing your stories. It is your …See details»
Contact Us - argenx
Argenx UK Ltd. Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG. Canada. 6220 Highway 7 West, Suite 301 Vaughan, Ontario L4H 0R1. Spain. argenx Spain …See details»
argenx | Board Committees
Mr. Krognes joined the argenx Board of Directors in February 2023 as a non-executive director and chairperson of the audit and compliance committee. Mr. ... Dr. Ana Céspedes is Chief …See details»
Home [www.argenxmedical.com]
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatchSee details»
argenx - Contacts, Employees, Board Members, …
Organization. argenx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 12. Number of Board Member and Advisor Profiles 2. Contacts 536. About. …See details»
Capitalization and Indebtedness - argenx Annual Report 2023
Dec 31, 2023 argenx Group. argenx Group; Shareholder Letter; 2023 In Brief; 2024 Outlook; Company Profile; Strategy and Objectives; Our Products and Product Candidates. Our …See details»
Annual Report 2022 | argenx – Home
Message to Our Shareholders. Commitment is the word that comes to mind when I look back at 2022 and all that we accomplished as a team. For the first time in our history, we were able to …See details»
Grants - argenx
However, argenx clinical interests will be prioritized. The approval of a grant application is competitive in nature and the final decision is made by the argenx grant review committee. ...See details»
Ethics and Responsibility - Argenx
At argenx, we are on a journey together to achieve the unthinkable. We are all working hard to build an integrated immunology company and reach patients. And in doing so, we are …See details»
Innovation - The Science of Collaboration - Argenx
The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic …See details»
ARGX-109, ARGX-220, ARGX-121 and ARGX-213 Development
Through the IIP, four new pipeline candidates were nominated in 2023, including: ARGX-213 targeting FcRn and furthering argenx’ leadership in this new class of medicine; ARGX-121 and …See details»
argenx | argenx Highlights 2025 Strategic Priorities
Jan 13, 2025 argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported …See details»
Immunology Innovation Program - argenx Annual Report 2022
Immunology Innovation Program Overview. Our IIP is a core business strategy of co-creation and innovation. The IIP also serves as our discovery engine to identify novel targets and together, …See details»
argenx Highlights FcRn Leadership with Long-term Data and ...
Mar 7, 2025 Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio …See details»
argenx to Present at TD Cowen 45th Annual Healthcare Conference
Feb 25, 2025 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced …See details»